Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Esomeprazole Magnesium Delayed?Release Capsules USP, 20 mg and 40 mg, a generic version of Nexium Delayed?Release Capsules, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals LP.
According to IQVIA sales data for the 12 month period ending March 2019, the Nexium Delayed? Release Capsules, 20 mg and 40 mg market achieved annual sales of approximately $395.1 million.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
